YAYLAGA Trademark
YAYLAGA is a USPTO trademark filed by Bristol-Myers Squibb Company. Status: Pending.
Trademark Facts
| Mark | YAYLAGA |
|---|---|
| Serial Number | 97261006 |
| Status | Pending |
| Filing Date | 2022-02-10 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Bristol-Myers Squibb Company |
| Attorney of Record | Marilyn F. Kelly |
| Prosecution Events | 38 |
| Latest Event | EXRA on 2026-04-29 |
Goods & Services
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use